<DOC>
	<DOCNO>NCT00692354</DOCNO>
	<brief_summary>The primary objective study determine safety , tolerability , dose-limiting toxicity ( DLT ) maximum tolerate dose ( MTD ) CHR-2797 administer orally , daily , patient advance solid tumour . The secondary objective study : - To determine pharmacokinetic parameter CHR-2797 administer orally increase dose level ; - To investigate pharmacodynamic effect CHR-2797 blood mononuclear cell , possible , tumour cell ; - To enable preliminary assessment anti-tumour activity CHR-2797 .</brief_summary>
	<brief_title>Safety Study Evaluate CHR-2797 Patients With Advanced Tumours</brief_title>
	<detailed_description />
	<mesh_term>Glycine</mesh_term>
	<criteria>Signed , inform consent Histological cytologically confirm malignant solid tumour refractory standard therapy standard therapy exist Evaluable disease Recovered acute adverse effect prior therapy ( exclude alopecia grade 1 neuropathy ) Adequate bone marrow , hepatic renal function include follow : 1 . Hb ≥ 9.0 g/dl , absolute neutrophil count ≥ 1.5 x 109/L , platelet ≥ 100x109/L 2 . Total bilirubin ≤ 1.5 x upper normal limit 3 . AST ALT ≤ 2.5 x upper normal limit ( ≤ 5 x UNL presence liver metastasis ) 4 . Creatinine ≤1.5 x upper normal limit Age &lt; 18 year Performance status ( PS ) &lt; 2 ( ECOG scale ) Estimated life expectancy great 3 month Female patient reproductive potential negative serum pregnancy test within 7 day treatment . Both woman men agree use medically acceptable method contraception throughout treatment period 3 month discontinuation treatment . Acceptable method contraception include IUD , oral contraceptive , subdermal implant double barrier ( condom contraceptive sponge contraceptive pessary ) Anticancer therapy include chemotherapy , radiotherapy , endocrine therapy , immunotherapy use investigational agent within 4 week prior study entry ( long period depend defined characteristic agent use e.g . 6 week mitomycin nitrosourea ) . In patient progressive disease ( PD ) , continuation LHRH agonists prostate cancer , bisphosphonates bone disease corticosteroid permit provide dose stable study Coexisting active infection serious concurrent illness Significant cardiovascular disease define 1 . History congestive heart failure require therapy 2 . History unstable angina pectoris myocardial infarction 6 month prior study entry 3 . Presence severe valvular heart disease 4 . Presence ventricular arrhythmia require treatment Any coexist medical condition Investigator 's judgement substantially increase risk associate patient 's participation study Psychiatric disorder alter mental status preclude understand informed consent process and/or completion necessary study Gastrointestinal disorder might interfere absorption study drug Persistent grade 2 great toxicity cause Patients know brain tumour metastasis exclude clinical study poor prognosis often develop progressive neurologic dysfunction would confound evaluation neurologic AEs Pregnant breastfeed woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Advanced</keyword>
	<keyword>Solid</keyword>
	<keyword>Tumour</keyword>
	<keyword>Tumor</keyword>
	<keyword>Oral</keyword>
</DOC>